MRI Background Parenchymal Enhancement, Breast Density and Breast Cancer Risk Factors: A Cross-sectional Study in Pre- and Post-menopausal Women
Overview
Authors
Affiliations
Breast tissue enhances on contrast MRI and is called background parenchymal enhancement (BPE). Having high BPE has been associated with an increased risk of breast cancer. We examined the relationship between BPE and the amount of fibroglandular tissue on MRI (MRI-FGT) and breast cancer risk factors. This was a cross-sectional study of 415 women without breast cancer undergoing contrast-enhanced breast MRI at Memorial Sloan Kettering Cancer Center. All women completed a questionnaire assessing exposures at the time of MRI. Prevalence ratios (PR) and 95% confidence intervals (CI) describing the relationship between breast cancer risk factors and BPE and MRI-FGT were generated using modified Poisson regression. In multivariable-adjusted models a positive association between body mass index (BMI) and BPE was observed, with a 5-unit increase in BMI associated with a 14% and 44% increase in prevalence of high BPE in pre- and post-menopausal women, respectively. Conversely, a strong inverse relationship between BMI and MRI-FGT was observed in both pre- (PR = 0.66, 95% CI 0.57, 0.76) and post-menopausal (PR = 0.66, 95% CI 0.56, 0.78) women. Use of preventive medication (e.g., tamoxifen) was associated with having low BPE, while no association was observed for MRI-FGT. BPE is an imaging marker available from standard contrast-enhanced MRI, that is influenced by endogenous and exogenous hormonal exposures in both pre- and post-menopausal women.
Kuling G, Brooks J, Curpen B, Warner E, Martel A J Med Imaging (Bellingham). 2025; 12(Suppl 2):S22002.
PMID: 40078986 PMC: 11894108. DOI: 10.1117/1.JMI.12.S2.S22002.
Nicosia L, Mariano L, Mallardi C, Sorce A, Frassoni S, Bagnardi V Cancers (Basel). 2025; 17(1.
PMID: 39796642 PMC: 11718959. DOI: 10.3390/cancers17010011.
Sachani P, Dhande R, Parihar P, Kasat P, Bedi G, Pradeep U Cureus. 2024; 16(9):e70226.
PMID: 39463566 PMC: 11512160. DOI: 10.7759/cureus.70226.
Magni V, Cozzi A, Muscogiuri G, Benedek A, Rossini G, Fanizza M Radiol Med. 2024; 129(9):1303-1312.
PMID: 39060886 DOI: 10.1007/s11547-024-01860-5.
Kong Y, Huang J, Ding Y, Chen S, Li Q, Xiong Y Clin Transl Oncol. 2024; 27(2):403-416.
PMID: 39012453 DOI: 10.1007/s12094-024-03563-9.